Physician

Hamdy A Mohtaseb, MD, FACP

According to 2025 Medicare claims, Hamdy Mohtaseb, MD, FACP (NPI: 1164423257) practices hematology/oncology in the Lake Havasu City-Kingman, AZ market, with the plurality of this provider's patient population coming from Mohave, AZ. This provider's primary affiliated billing organization is HEMATOLOGY-ONCOLOGY ASSOCIATES OF NORTH JERSEY LLC (NPI: 1972776672; TIN: 223746905) and primary practice location at 86442-7860. Mohtaseb is affiliated with the P3 Health Partners REACH ACO LLC (ACO ID: D0327), participating under the REACH model.

Mohtaseb's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 568 traditional Medicare patients, billed 210,460 HCPCS/CPT codes, and received $2,893,230 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 230 prescription claims across 74 beneficiaries totaling $806,472 in drug costs, led by Procrit (Epoetin Alfa). DME data shows 68 claims. Open Payments data shows 107 records totaling $47,601. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,453,521 and ending at $2,893,230. Concurrently, Part D prescription costs have fallen sharply in recent years, from $502,563 to $806,472. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,015 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	688	187,399	$2,453,521
2016	1,145	204,013	$2,481,860
2017	1,286	256,406	$3,212,176
2018	1,059	286,337	$2,577,136
2019	1,015	181,852	$2,444,095
2020	890	86,742	$1,277,998
2021	462	70,318	$874,200
2022	451	142,557	$1,806,463
2023	502	165,704	$1,895,535
2024	568	210,460	$2,893,230

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	208	1,078	$502,563
2016	239	980	$844,509
2017	300	1,156	$2,921,080
2018	273	1,184	$2,811,941
2019	210	858	$3,133,469
2020	190	883	$4,444,155
2021	90	369	$3,401,101
2022	102	401	$3,387,457
2023	52	140	$425,268
2024	74	230	$806,472

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	40	482	$28,503
2016	49	500	$27,552
2017	45	381	$14,627
2018	N/R	125	$8,507
2019	11	84	$3,060
2020	N/R	30	$1,598
2021	N/R	11	$2
2022	N/R	66	$9
2023	N/R	N/R	N/R
2024	N/R	68	$6

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	79	98	$131
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	98	98	$122
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	324	638	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	319	647	$65
96372	Injection of drug or substance under skin or into muscle	131	810	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Procrit	Epoetin Alfa	25	700	$100,787
Ondansetron Hcl	Ondansetron Hcl	14	430	$213
Letrozole	Letrozole	30	1,920	$196

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	N	N/R	68	$6

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	104	$2,626	SOBI, INC
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$44,976	SANOFI US SERVICES INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hamdy A. Mohtaseb, MD, FACP?

Tedicare shows public-source Medicare data for Hamdy A. Mohtaseb, MD, FACP (NPI 1164423257), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hamdy A. Mohtaseb, MD, FACP have ACO affiliation data?

Hamdy A. Mohtaseb, MD, FACP is shown with ACO affiliation data for P3 Health Partners REACH ACO LLC (REACH, ACO ID D0327).

What billing organization is linked to Hamdy A. Mohtaseb, MD, FACP?

Hamdy A. Mohtaseb, MD, FACP is linked to HEMATOLOGY-ONCOLOGY ASSOCIATES OF NORTH JERSEY LLC (billing NPI 1972776672) in the available physician profile data.

Does Hamdy A. Mohtaseb, MD, FACP have Open Payments data?

Hamdy A. Mohtaseb, MD, FACP has 107 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.